Clinically Feasible Biofilm Susceptibility Assay for Isolates of *Pseudomonas aeruginosa* from Patients with Cystic Fibrosis

Samuel M. Moskowitz, Jessica M. Foster, Julia Emerson, and Jane L. Burns

Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington 98195; and Divisions of Pulmonary Medicine and Infectious Diseases, Children's Hospital and Regional Medical Center, Seattle, Washington 98105

Received 26 September 2003/Returned for modification 27 October 2003/Accepted 6 February 2004

*Pseudomonas aeruginosa* is the predominant cause of chronic airway infection in cystic fibrosis (CF). CF airway isolates are often tested for antibiotic susceptibility but are rarely eradicated by the antibiotics identified as potentially effective. The growth state of *P. aeruginosa* in CF airways is probably different from that exhibited under conventional susceptibility testing conditions and may represent a bacterial biofilm. Biofilm susceptibility testing methods were adapted to create an assay for implementation in a clinical microbiology laboratory. This assay gave reproducible results when examined in 300 paired determinations with 12 antimicrobial agents, with a serious error rate of 5.7%. The biofilm assay was used retrospectively to test these 12 agents against 94 isolates from 41 CF patients. The biofilm inhibitory concentrations (BICs) were much higher than the corresponding conventionally determined MICs for the β-lactam antibiotics (median values: aztreonam, >128 μg/ml versus 4 μg/ml; ceftazidime, 128 μg/ml versus 2 μg/ml; piperacillin-tazobactam, 256 μg/ml versus 4 μg/ml; and ticarcillin-clavulanate, 512 μg/ml versus 16 μg/ml, respectively) and doxycycline (>64 μg/ml versus 16 μg/ml); and similar for meropenem (4 μg/ml versus ≤1 μg/ml), ciprofloxacin (0.5 μg/ml versus 1 μg/ml), and the aminoglycosides amikacin (32 μg/ml versus 16 μg/ml), gentamicin (16 μg/ml versus 8 μg/ml), and tobramycin (4 μg/ml versus 2 μg/ml). The median BIC for azithromycin was 2 μg/ml, whereas isolates were uniformly resistant when tested by standard methods. This demonstrates the feasibility of adapting biofilm susceptibility methods to the clinical microbiology laboratory and opens the way to examining whether biofilm testing might be used to select more effective antibiotic combinations for CF airway infections than methods in current use.

Chronic *Pseudomonas aeruginosa* airway infections remain the primary cause of morbidity and mortality in the cystic fibrosis (CF) population (22). Young children with CF may be infected as early as 6 months of age, based on cultures of bronchoalveolar lavage fluid and positive serology (3, 6, 26, 35), and *P. aeruginosa* becomes chronic in the first decade of life with pulmonary exacerbations increasing in frequency (10). Antibiotic therapy, directed by standardized susceptibility testing, has traditionally been used to treat symptomatic CF patients with chronic infection (22, 29). In the setting of pulmonary exacerbation, antipseudomonal therapy, frequently consisting of a β-lactam and an aminoglycoside, may result in clinical improvement and a decrease in bacterial burden; however, eradication of infection is quite rare.

Despite recommendations for the use of standard susceptibility testing in CF (29), the methods used for this testing were developed specifically to direct therapy for the treatment of acute bloodstream and urinary tract infections and have only been fully validated for these infections. The clinical utility of standard susceptibility testing in CF has been called into question based on data recently reported by Smith et al. (32). This is not surprising since CF chronic airway infections differ significantly from acute bloodstream and urinary tract infections; thus, it seems reasonable that testing strategies should reflect these differences.

Bacteria in CF airways appear to be very slow growing or even in stationary phase, are likely to be in an anaerobic or microaerophilic environment (39), and may even constitute a biofilm (11, 31). Bacterial biofilms are inherently resistant to antimicrobial agents, and sessile cells are much less susceptible than when growing planktonically (18, 20, 34). These findings are highly reminiscent of CF airway infections (21). Thus, the inability to eradicate *P. aeruginosa* chronic infections in CF may result, in part, from treatment regimens based on susceptibility testing that only poorly reflects the growth state of bacteria in CF airways. The response to antibiotic exposure of stationary-phase, microaerophilic bacteria growing as biofilms in the clinical laboratory may better predict the response of CF patients to antimicrobial therapy.

The present study was performed to examine the susceptibility of a large number of CF clinical isolates of *P. aeruginosa* growing as biofilms and to compare these results with standard MIC determinations. Evidence of in vitro biofilm activity and of different susceptibility patterns by the two methods would support further examination of the clinical utility of biofilm susceptibility testing in CF.

**Materials and Methods**

Bacterial strains. *P. aeruginosa* isolates (n = 94) were studied from 41 patients of the Cystic Fibrosis Center at Children's Hospital and Regional Medical Center, in Seattle, Wash. Approval for the study was obtained from the Institutional Review Board. The subjects met the following eligibility criteria: a diag-
BIOFILM SUSCEPTIBILITY ASSAY

FIG. 1. Biofilm susceptibility assay. See the text for details.

TABLE 1. Antibiotics tested

<table>
<thead>
<tr>
<th>Antibiotic (no. of strains tested)</th>
<th>BIC test</th>
<th>MIC test</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group 1 agents (94)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amikacin</td>
<td>0.05-128</td>
<td>0.5-128</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>0.05-32</td>
<td>NA a</td>
</tr>
<tr>
<td>Aztreonam</td>
<td>2-128</td>
<td>1-128</td>
</tr>
<tr>
<td>Ceftazidime</td>
<td>2-128</td>
<td>0.5-64</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>0.25-16</td>
<td>0.12-8</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>0.05-32</td>
<td>NA</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>1-64</td>
<td>0.25-32</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>1-64</td>
<td>1-64</td>
</tr>
<tr>
<td>Meropenem</td>
<td>1-64</td>
<td>0.5-32</td>
</tr>
<tr>
<td>Piperacillin-tazobactam b</td>
<td>16-512</td>
<td>0.5-1024</td>
</tr>
<tr>
<td>Ticarcillin-clavulanate b</td>
<td>16-512</td>
<td>2-4096</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>1-64</td>
<td>1-512</td>
</tr>
<tr>
<td><strong>Group 2 agents (20)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cefepime</td>
<td>1-256</td>
<td>0.5-64</td>
</tr>
<tr>
<td>Cefoxitin</td>
<td>0.25-64</td>
<td>0.25-64</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>1-256</td>
<td>2-64</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>0.0625-16</td>
<td>0.0625-16</td>
</tr>
<tr>
<td>Colistin</td>
<td>0.5-128</td>
<td>0.5-128</td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>0.25-64</td>
<td>0.25-64</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>0.125-32</td>
<td>0.125-32</td>
</tr>
<tr>
<td>Trimethoprim-sulfamethoxazole c</td>
<td>0.25-64</td>
<td>0.25-64</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>0.5-128</td>
<td>0.5-128</td>
</tr>
</tbody>
</table>

a NA, not available. MIC testing was not performed.

b For standard susceptibility testing (MIC) of the β-lactam and β-lactamase inhibitor combinations, only the β-lactam (without inhibitor) was tested. However, the MIC values should predict results for the combination.

c Concentration represents the sulfamethoxazole component.
tion methods to the clinical laboratory, as well as to mimic conditions in the CF lung more closely, several modifications of these methods were tested. Twelve CF P. aeruginosa isolates were used for this testing, six of which were mucoid.

To test the effect of growth medium on biofilm formation, biofilms were grown on pegs for 20 h in three different medium formulations. A minimal medium broth supplemented with 0.4% arginine (which P. aeruginosa can utilize as an a terminal electron acceptor under hypoxic conditions) was compared to CAMHB (the NCCLS-approved medium for susceptibility testing). As shown in Fig. 2, CAMHB or CAMHB with 0.4% arginine resulted in more luxuriant biofilm growth than with minimal medium for the majority of isolates tested.

Biofilms are often grown in the presence of shear stress. In CF, the mucus rheological properties and mucociliary clearance are markedly altered. Thus, the extent to which biofilms in CF airways are exposed to shear forces is not known. To test the effect of shear stress on biofilm growth in this assay system, the formation of biofilms grown without movement of the surrounding medium was compared to those exposed to rocking at 20 Hz. Biofilm growth in CAMHB under each of these conditions was quantified by crystal violet staining. Incubation of the growth plates without motion consistently resulted in comparable growth compared to incubation in the presence of shear stress (Fig. 3).

Several susceptibility protocols call for removing biofilms from the pegs by sonication for 5 min (9, 34). Although this removal method is effective, it is relatively impractical in the clinical laboratory setting, where multiple isolates must be processed simultaneously; most bath sonicators can only hold two plates, and it is possible that the water from the bath might...
enter and contaminate the plates. Thus, we evaluated centrifugation at 805 × g for 20 min as an alternative method of biofilm removal. Initially, these removal methods were compared by crystal violet staining of biofilm material remaining on pegs after processing. Centrifugation and sonication left comparable amounts on the pegs (results not shown). To examine this further, the two methods were compared quantitatively by counting CFU in recovery wells. Centrifugation at 805 × g for 20 min and sonication for 5 min gave similar results (Fig. 4) in that both methods were reproducible, with little variability. However, the mean CFU/well was 0.6 log_{10} lower for centrifugation compared to sonication. Whether this difference in bacterial recovery could translate to altered biofilm susceptibility and thus to altered drug selection in the clinical setting is unknown.

To determine whether the removal method affects susceptibility results, a *P. aeruginosa* quality control strain was tested. Comparison of BIC values for 12 antibiotics against strain ATCC 27853 by each removal method demonstrated that 11 of 12 pairs of values were within one twofold dilution, and seven pairs were identical. The twelfth pair of values, for meropenem, was within two twofold dilutions, and both were consistent with susceptibility of the strain, based on NCCLS breakpoints (19).

In addition to an assessment of the effects of antibiotic exposure, the adequacy of biofilm formation was examined in the growth plates. Nonantibiotic exposed pegs were used as growth controls. Bacteria were centrifuged from pegs after antibiotic exposure and washing and growth over 6 h determined by OD_{650}. The range of OD_{650} differences in the nonantibiotic growth controls was 0 to 0.3547 (mean, 0.1394), with 74% of isolates above the cutoff for adequate biofilm growth (0.05).

**Reproducibility of BIC testing.** To determine reproducibility, the biofilm susceptibilities to the 12 group 1 agents were determined in duplicate for 25 isolates from nine of the subjects. Interpretable data were obtained for 260 of 300 isolate-antibiotic pairs; data for the remaining pairs was not available due to out-of-range values for quality control strains (n = 12 pairs, all with ticarcillin-clavulanate) or uninterpretable results for one of the pair (n = 28 pairs). The reproducibility for each pair of BIC determinations and the NCCLS-defined error rates.
TABLE 2. Error rates by duplicate assay discordance for group 1 agents

<table>
<thead>
<tr>
<th>Antibiotic (no. of strains)</th>
<th>≤2 dilutions</th>
<th>Serious errors</th>
<th>Minor errors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amikacin (24)</td>
<td>23 (96)</td>
<td>1 (4.2)</td>
<td>4 (16.6)</td>
</tr>
<tr>
<td>Azithromycin (25)</td>
<td>21 (84)</td>
<td>2 (8.0)</td>
<td>1 (4.0)</td>
</tr>
<tr>
<td>Aztreonam (18)</td>
<td>17 (94)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ceftazidime (23)</td>
<td>18 (78)</td>
<td>2 (8.7)</td>
<td>3 (13.0)</td>
</tr>
<tr>
<td>Ciprofloxacin (23)</td>
<td>19 (83)</td>
<td>0</td>
<td>1 (4.3)</td>
</tr>
<tr>
<td>Clarithromycin (22)</td>
<td>20 (91)</td>
<td>0</td>
<td>1 (4.5)</td>
</tr>
<tr>
<td>Doxycycline (22)</td>
<td>22 (100)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Gentamicin (23)</td>
<td>21 (91)</td>
<td>1 (4.3)</td>
<td>7 (30.4)</td>
</tr>
<tr>
<td>Meropenem (22)</td>
<td>13 (59)</td>
<td>4 (18.1)</td>
<td>3 (13.6)</td>
</tr>
<tr>
<td>Piperacillin-tazobactam (20)</td>
<td>16 (80)</td>
<td>5 (20.0)</td>
<td>NA</td>
</tr>
<tr>
<td>Ticarcillin-clavulanate (13)</td>
<td>12 (92)</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td>Tobramycin (25)</td>
<td>25 (100)</td>
<td>0</td>
<td>4 (16.0)</td>
</tr>
<tr>
<td>Total (260)</td>
<td>227 (87)</td>
<td>15 (5.7)</td>
<td>24 (9.2)</td>
</tr>
</tbody>
</table>

a A total of 25 strains were tested for each agent (possible 300 paired determinations).

b NA, not applicable. There is no intermediate category for ticarcillin-clavulanate and piperacillin-tazobactam.

were determined (Table 2). Overall, 87% of the paired BIC values were within two dilutions of each other, with the most reproducible results for doxycycline and tobramycin (100%) and the lowest results for meropenem (59%). No serious errors were identified for aztreonam, ciprofloxacin, clarithromycin, doxycycline, ticarcillin-clavulanate, and tobramycin. The highest percentages of serious errors were for piperacillin-tazobactam (20.0%) and meropenem (18.2%). The serious error rate for all agents was 5.7% overall.

Comparison of MIC and BIC values. BICs for the 12 group 1 antibiotics were determined for 94 clinical isolates of P. aeruginosa from 41 patients with CF by biofilm testing. Table 3 presents the MIC50, MIC90, BIC50, and BIC90 for these isolates. Percentile-based MIC and BIC values were similar for some drugs (amikacin, ciprofloxacin, and tobramycin), whereas other drugs had BIC percentiles that were somewhat higher than their MIC percentiles (gentamicin and meropenem). The β-lactam antibiotics (aztreonam, ceftazidime, piperacillin-tazobactam, and ticarcillin-clavulanate) and doxycycline had BIC percentiles much higher than their MICs. For two drugs (azithromycin and clarithromycin), no MICs were available because P. aeruginosa are uniformly considered to be resistant in standard susceptibility testing. However, azithromycin appeared quite active against P. aeruginosa biofilms under these assay conditions.

In addition to testing the antibiofilm activity of 12 agents that are widely used in the United States for the treatment of CF-associated P. aeruginosa airway infections (group 1 agents), 9 additional antimicrobial agents (group 2 agents) were tested against a subset of isolates (n = 20). This included antibiotics that lack conventional activity against P. aeruginosa but that might have antibiofilm effects (e.g., anaerobic agents), as well as anti-pseudomonal antibiotics that are not commonly used either because of their recent introduction to clinical practice (e.g., cefepime) or toxicity (e.g., chloramphenicol and colistin). Of these, only levofloxacin displayed significant antibiofilm activity (Table 4) comparable to that of ciprofloxacin. Cefepime displayed anti-pseudomonal activity in the conventional MIC assay, as expected, but like the other β-lactam antibiotics tested, displayed generally poor antibiofilm activity. Colistin also displayed conventional anti-pseudomonal activity but not significant antibiofilm activity, although this may have been due to inoculum size differences between the methods, an effect to which colistin susceptibility testing is sensitive.

### DISCUSSION

We have utilized a previously developed technique to evaluate biofilm susceptibility testing of CF clinical isolates (1, 9, 34). Some of the growth and testing conditions that are used in antibiotic susceptibility assays deliberately reflect in vivo conditions during human infection, whereas other aspects of these methods reflect practical considerations or are purely arbitrary. Recognizing that many aspects of existing methods are arbitrary, we adapted the published methods to (i) reflect conditions in the CF lung more accurately and (ii) facilitate performance in a clinical laboratory setting. These methodological modifications appear to affect the results of the test only min-

**TABLE 3. Comparison of biofilm and standard susceptibility testing of P. aeruginosa isolates for group 1 agents**

<table>
<thead>
<tr>
<th>Antibiotic (no. of strains)a</th>
<th>Conc. (µg/ml)</th>
<th>BIC</th>
<th>MIC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BIC50</td>
<td>BIC90</td>
<td>Range</td>
</tr>
<tr>
<td>Amikacin (90)</td>
<td>32</td>
<td>256</td>
<td>4–256</td>
</tr>
<tr>
<td>Azithromycin (90)</td>
<td>2</td>
<td>32</td>
<td>≤0.5–32</td>
</tr>
<tr>
<td>Aztreonam (85)</td>
<td>&gt;128</td>
<td>&gt;128</td>
<td>≤2–128</td>
</tr>
<tr>
<td>Ceftazidime (88)</td>
<td>128</td>
<td>&gt;128</td>
<td>≤2–128</td>
</tr>
<tr>
<td>Ciprofloxacin (90)</td>
<td>0.5</td>
<td>4</td>
<td>&lt;0.25–16</td>
</tr>
<tr>
<td>Clarithromycin (90)</td>
<td>32</td>
<td>&gt;32</td>
<td>≤0.5–32</td>
</tr>
<tr>
<td>Dicloxacillin (86)</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>≤1–64</td>
</tr>
<tr>
<td>Gentamicin (90)</td>
<td>16</td>
<td>&gt;64</td>
<td>≤1–64</td>
</tr>
<tr>
<td>Meropenem (87)</td>
<td>4</td>
<td>64</td>
<td>≤1–64</td>
</tr>
<tr>
<td>Piperacillin-tazobactamb (85)</td>
<td>256</td>
<td>&gt;512</td>
<td>≤16–512</td>
</tr>
<tr>
<td>Ticarcillin-clavulanateb (72)</td>
<td>512</td>
<td>&gt;512</td>
<td>≤16–512</td>
</tr>
<tr>
<td>Tobramycin (92)</td>
<td>4</td>
<td>32</td>
<td>≤1–64</td>
</tr>
</tbody>
</table>

a A total of 94 strains were tested.
b For standard susceptibility testing (MIC) of the β-lactam and β-lactamase inhibitor combinations, only the β-lactam (without inhibitor) was tested. However, the MIC values should predict results for the combination.
Validation of the reproducibility of the modified methodology, as well as determination of NCCLS-defined error rates, was deemed important in considering this assay as a potential clinical test. The concordance between duplicate determinations and the observed error rates for BIC testing was similar to that previously reported for standard methods. The totals of 5.7% serious errors and 9.2% minor errors are within an acceptable range when viewed in light of our previous examination of susceptibility testing methods in CF isolates of P. aeruginosa (8). Also, as previously reported for MIC testing, the greatest numbers of serious errors for BIC testing were seen with β-lactam antibiotics, and the greatest numbers of minor errors with the aminoglycosides. Of particular note, some of the serious errors represented a difference of only two twofold dilutions.

No predominant pattern of P. aeruginosa CF biofilm susceptibility emerged among the 94 isolates tested. The ranges of BIC values for most drugs were broad, and it was not possible to select a single best antibiotic agent or combination of agents based on biofilm susceptibility testing of this group of isolates. This indicates that the optimal combination of antibiotic agents must be determined through antibiotic susceptibility testing of individual isolates. This is similar to the results reported for synergy testing, where it is not possible to predict the most active combinations by studying populations of organisms (28).

Studies of biofilm susceptibility testing have been performed on a small scale for years, with reports of increased clinical activity of drugs known to have activity against biofilms in both in vitro and in vivo models compared to standard therapy. Infections on indwelling devices such as intravenous, urinary, and peritoneal dialysis catheters and endotracheal tubes are perhaps the best studied (2, 30). In these studies, both standard antibiotics delivered at higher doses and agents not previously described as having antibacterial activity have been demonstrated to be effective against biofilms. In addition, there are numerous anecdotes of patients responding to therapy based on either direct biofilm susceptibility testing or extrapolated from in vitro testing of different drug classes (Howard Ceri, University of Calgary [unpublished data]).

Biofilm susceptibility testing of nearly 100 P. aeruginosa strains from individuals with CF demonstrated diminished activity of several antipseudomonal antibiotics, compared to standard in vitro susceptibility testing. With recent reports of biofilm formation in CF airway infections (11, 17, 31, 39), these data raise the possibility that current antimicrobial regimens based on standard susceptibility testing may result in suboptimal drug combinations. This may explain the failure of treatment regimens based upon standard susceptibility testing to eradicate P. aeruginosa from CF airways. Studies of young patients with CF who have recent acquisition of P. aeruginosa and of older patients with non-CF bronchiectasis have shown evidence of eradication (4, 13, 14, 24, 37). In contrast, although antibiotic therapy may improve clinical status and reduce bacterial burden by up to 2 log<sub>10</sub> in older CF patients (23, 25, 33), efforts to eradicate P. aeruginosa in the setting of more established CF airway infections have generally failed. Among a group of CF patients with chronic persistent P. aeruginosa infection, 28 days of tobramycin inhalation decreased the geometric mean bacterial density by only 1.9 log<sub>10</sub> CFU/g (23).

A tendency toward biofilm formation in chronic CF airway infection may also contribute to this difference in eradication. Biofilm formation has been demonstrated in CF patients with chronic P. aeruginosa infection (31), and P. aeruginosa biofilm properties, including antibiotic resistance, have been correlated with mucoidy (15). This association is more likely related to shared regulatory control (36) than to involvement of alginate itself in biofilm formation (40). Both mucoidy and biofilm formation are associated with chronic but not transient P. aeruginosa infection of CF airways, since only 17% of CF patients have mucoid isolates in the first 3 years of life (6), whereas up to 94% of older patients may have them (5).

In contrast to the finding that many drugs with good activity in conventional testing did not have biofilm activity, at least one agent, azithromycin, appeared much more active against biofilm-grown P. aeruginosa. This has previously been reported in non-CF isolates (16). The antibiotic activity of azithromycin is particularly significant in the face of recent reports of the clinical efficacy of azithromycin in CF patients with P. aeruginosa infection (12, 27, 38).

Although antibiotic susceptibility testing is recommended for CF isolates of P. aeruginosa (29) and special techniques are advised (7, 8), there are no prospective data to demonstrate the clinical efficacy of using the results to direct patient care. A recent retrospective analysis of data from the placebo group from the phase III clinical trials of inhaled tobramycin suggests the lack of utility of standard testing (32). In that study, 76 of the 262 patients in the placebo arm experienced a pulmonary...
exacerbation during the trial for which they received intrave-
nous tobramycin and ceftazidime therapy. The results of stan-
dard in vitro susceptibility testing for both the most prevalent
strain and the most resistant strain from each patient did not
correlate with clinical improvement. These results suggest that
the use of standard broth microdilution susceptibility testing to
guide therapy may not improve clinical outcomes and raises
the question of whether alternative methods that more accu-
rately simulate growth conditions in the CF airway might guide
therapy more effectively.

The results of the present study demonstrate marked differ-
ences between the results of susceptibility testing performed
according to standard NCCLS guidelines and testing per-
formed with biofilm-grown CF isolates of P. aeruginosa.
Whether these in vitro differences will translate to improved
bacterial killing in vivo and better clinical response to therapy
is not known. Nonetheless, the results of the present study
suggest the utility of conducting a clinical trial in CF airway
infections to compare the efficacy of antibiotic therapy based
on biofilm susceptibility testing with that based on standard
testing.

ACKNOWLEDGMENTS

This study was funded by a grant to S.M.M. from the Research
Endowment Fund at Children’s Hospital and Regional Medical Center
and by the CF Research Development Program at the University of
Washington.

We thank Marcella Harris for assistance with data management.

REFERENCES

1. Aaron, S. D., W. Ferris, K. Ramotar, K. Vandemheen, F. Chan, and R.
Saginur. 2002. Single and combination antibiotic susceptibilities of plank-
tonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured

2. Adair, C. G., S. P. Gorman, L. M. Byers, D. S. Jones, B. Feron, M. Crowe,
endotracheal tube biofilm by nebulized gentamicin. Intensive Care Med. 28:
426–431.

Adair, C. G., S. P. Gorman, L. M. Byers, D. S. Jones, B. Feron, M. Crowe,
endotracheal tube biofilm by nebulized gentamicin. Intensive Care Med. 28:
426–431.

Adair, C. G., S. P. Gorman, L. M. Byers, D. S. Jones, B. Feron, M. Crowe,
endotracheal tube biofilm by nebulized gentamicin. Intensive Care Med. 28:
426–431.

Adair, C. G., S. P. Gorman, L. M. Byers, D. S. Jones, B. Feron, M. Crowe,
endotracheal tube biofilm by nebulized gentamicin. Intensive Care Med. 28:
426–431.

Adair, C. G., S. P. Gorman, L. M. Byers, D. S. Jones, B. Feron, M. Crowe,
endotracheal tube biofilm by nebulized gentamicin. Intensive Care Med. 28:
426–431.

Adair, C. G., S. P. Gorman, L. M. Byers, D. S. Jones, B. Feron, M. Crowe,
endotracheal tube biofilm by nebulized gentamicin. Intensive Care Med. 28:
426–431.

Adair, C. G., S. P. Gorman, L. M. Byers, D. S. Jones, B. Feron, M. Crowe,
endotracheal tube biofilm by nebulized gentamicin. Intensive Care Med. 28:
426–431.


10. Armstrong, D. S., K. Grimwood, J. B. Carlin, R. Carzino, J. P. Gutierrez, J.
Adair, C. G., S. P. Gorman, L. M. Byers, D. S. Jones, B. Feron, M. Crowe,
endotracheal tube biofilm by nebulized gentamicin. Intensive Care Med. 28:
426–431.

Adair, C. G., S. P. Gorman, L. M. Byers, D. S. Jones, B. Feron, M. Crowe,
endotracheal tube biofilm by nebulized gentamicin. Intensive Care Med. 28:
426–431.

Adair, C. G., S. P. Gorman, L. M. Byers, D. S. Jones, B. Feron, M. Crowe,
endotracheal tube biofilm by nebulized gentamicin. Intensive Care Med. 28:
426–431.

Adair, C. G., S. P. Gorman, L. M. Byers, D. S. Jones, B. Feron, M. Crowe,
endotracheal tube biofilm by nebulized gentamicin. Intensive Care Med. 28:
426–431.

Adair, C. G., S. P. Gorman, L. M. Byers, D. S. Jones, B. Feron, M. Crowe,
endotracheal tube biofilm by nebulized gentamicin. Intensive Care Med. 28:
426–431.

Adair, C. G., S. P. Gorman, L. M. Byers, D. S. Jones, B. Feron, M. Crowe,
endotracheal tube biofilm by nebulized gentamicin. Intensive Care Med. 28:
426–431.

Adair, C. G., S. P. Gorman, L. M. Byers, D. S. Jones, B. Feron, M. Crowe,
endotracheal tube biofilm by nebulized gentamicin. Intensive Care Med. 28:
426–431.

Adair, C. G., S. P. Gorman, L. M. Byers, D. S. Jones, B. Feron, M. Crowe,
endotracheal tube biofilm by nebulized gentamicin. Intensive Care Med. 28:
426–431.


